TR200200401T2 - Mycophenolate mofetil with PEG-IFN-a - Google Patents
Mycophenolate mofetil with PEG-IFN-aInfo
- Publication number
- TR200200401T2 TR200200401T2 TR2002/00401T TR200200401T TR200200401T2 TR 200200401 T2 TR200200401 T2 TR 200200401T2 TR 2002/00401 T TR2002/00401 T TR 2002/00401T TR 200200401 T TR200200401 T TR 200200401T TR 200200401 T2 TR200200401 T2 TR 200200401T2
- Authority
- TR
- Turkey
- Prior art keywords
- ifn
- peg
- mycophenolate mofetil
- treatment
- therapeutically effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Mikofenolik asidin farmasötik açidan kabul edilebilir bir tuzu veya ön ilacindan terapötik olarak etkili bir miktar ile birlikte IFN-a veya PEG-IFN-a'dan terapötik olarak etkili bir miktarin karaciger hastaliklari hastalarinin tedavi edilmesi amaçli ilaçlarin üretilmesinde kullanilmasi. Bilesenler en azindan adi geçen hastanin dis kaninda bulunan HCV-RNA miktarini, tedavi bittikten sonra 24.haftada 100 kopya/ml'nin altina indirmek için yeterli bir süreyle birlikte verilir.The use of a therapeutically effective amount of a pharmaceutically acceptable salt or prodrug of mycophenolic acid, as well as a therapeutically effective amount of IFN-a or PEG-IFN-a, in the manufacture of medicaments for the treatment of patients with liver disease. The components are given together for a sufficient time to reduce the amount of HCV-RNA present in the outer blood of the named patient, below 100 copies / ml at 24 weeks after treatment.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99115950 | 1999-08-13 | ||
| US18790700P | 2000-03-08 | 2000-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200200401T2 true TR200200401T2 (en) | 2002-06-21 |
Family
ID=29762814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2002/00401T TR200200401T2 (en) | 1999-08-13 | 2000-08-08 | Mycophenolate mofetil with PEG-IFN-a |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1220683A2 (en) |
| JP (1) | JP2003507339A (en) |
| CN (1) | CN1368887A (en) |
| AU (1) | AU7408200A (en) |
| BR (1) | BR0013252A (en) |
| CA (1) | CA2380653A1 (en) |
| HU (1) | HUP0202525A3 (en) |
| MX (1) | MXPA02001296A (en) |
| PE (1) | PE20010490A1 (en) |
| PL (1) | PL357367A1 (en) |
| RU (1) | RU2002105485A (en) |
| TR (1) | TR200200401T2 (en) |
| WO (1) | WO2001012214A2 (en) |
| ZA (1) | ZA200200280B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0307553D0 (en) * | 2003-04-01 | 2003-05-07 | Novartis Ag | Organic compounds |
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| ATE428714T1 (en) | 2004-02-24 | 2009-05-15 | Japan Tobacco Inc | CONDENSED HETEROTETRACYCLIC COMPOUNDS AND THEIR USE AS HCV POLYMERASE INHIBITORS |
| ES2349472T3 (en) * | 2004-08-12 | 2011-01-03 | Schering Corporation | STABLE FORMULATION OF PEGILATED INTERFERON. |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| US8623348B2 (en) * | 2009-03-27 | 2014-01-07 | Jw Pharmaceutical Corporation | Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| EA201490837A1 (en) | 2011-10-21 | 2014-11-28 | Эббви Инк. | METHODS OF TREATING HCV, INCLUDING, AT THE LITERATURE, TWO ANTI-VIRAL AGENTS OF DIRECT ACTION, RIBAVIRIN, BUT NOT INTERFERON |
| AU2013201532B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| SI3215193T1 (en) * | 2014-11-06 | 2024-02-29 | Pharmaessentia Corporation | Dosage regimen for pegylated interferon |
| EA201892448A1 (en) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| MY125300A (en) * | 1999-02-26 | 2006-07-31 | Inst Of Molecular And Cell Biology | Synergistic combination for treatment of viral-mediated diseases |
-
2000
- 2000-08-08 AU AU74082/00A patent/AU7408200A/en not_active Abandoned
- 2000-08-08 RU RU2002105485/15A patent/RU2002105485A/en not_active Application Discontinuation
- 2000-08-08 TR TR2002/00401T patent/TR200200401T2/en unknown
- 2000-08-08 EP EP00962297A patent/EP1220683A2/en not_active Withdrawn
- 2000-08-08 PL PL00357367A patent/PL357367A1/en not_active Application Discontinuation
- 2000-08-08 HU HU0202525A patent/HUP0202525A3/en unknown
- 2000-08-08 PE PE2000000804A patent/PE20010490A1/en not_active Application Discontinuation
- 2000-08-08 WO PCT/EP2000/007666 patent/WO2001012214A2/en not_active Ceased
- 2000-08-08 CN CN00811397A patent/CN1368887A/en active Pending
- 2000-08-08 BR BR0013252-7A patent/BR0013252A/en not_active IP Right Cessation
- 2000-08-08 MX MXPA02001296A patent/MXPA02001296A/en unknown
- 2000-08-08 JP JP2001516559A patent/JP2003507339A/en active Pending
- 2000-08-08 CA CA002380653A patent/CA2380653A1/en not_active Abandoned
-
2002
- 2002-01-11 ZA ZA200200280A patent/ZA200200280B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1368887A (en) | 2002-09-11 |
| CA2380653A1 (en) | 2001-02-22 |
| PL357367A1 (en) | 2004-07-26 |
| JP2003507339A (en) | 2003-02-25 |
| WO2001012214A2 (en) | 2001-02-22 |
| ZA200200280B (en) | 2003-04-11 |
| EP1220683A2 (en) | 2002-07-10 |
| PE20010490A1 (en) | 2001-04-27 |
| HUP0202525A2 (en) | 2002-11-28 |
| HUP0202525A3 (en) | 2003-11-28 |
| WO2001012214A3 (en) | 2001-10-04 |
| AU7408200A (en) | 2001-03-13 |
| BR0013252A (en) | 2002-04-16 |
| RU2002105485A (en) | 2004-01-27 |
| MXPA02001296A (en) | 2002-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003119460A (en) | APPLICATION OF PEG-INTERFERON-A (PEG-INF-A) AND RIBAVIRIN FOR TREATMENT OF CHRONIC HEPATITIS C | |
| DE69713526D1 (en) | SOLUBLE PACLITAXEL PRODRUGS | |
| TR200200401T2 (en) | Mycophenolate mofetil with PEG-IFN-a | |
| DK275488D0 (en) | indolone derivatives | |
| KR920700200A (en) | 19-nor-vitamin D compound | |
| LU91037I2 (en) | Somatulina autogel | |
| ES2178430T3 (en) | USE OF GELIFICABLE PHARMACEUTICAL COMPOSITIONS IN PARODONTOLOGY. | |
| IL112667A0 (en) | 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them | |
| BR9916860A (en) | Method of reducing blood cholesterol and / or other blood glycerides in a mammal individual, preparation in the form of a dosage unit, and, set to orally administer the same | |
| TR200101633T2 (en) | Pharmaceutical composition | |
| CA2302568A1 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
| DE69333387D1 (en) | Pharmaceutical compositions containing norastemizole. | |
| KR970025615A (en) | Cancer metastasis inhibitor | |
| KR950007848A (en) | Treatment of Anxiety with (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide | |
| AR012731A1 (en) | USE OF A TAXANE DERIVATIVE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, USE OF A BIODICABILITY IMPROVEMENT AGENT OF SUCH A DERIVATIVE ORAL DOSAGE FORM AND UNDERSTANDING ITEM AND METHOD FOR FORMING A BIO-AVAILABLE ACTIVE AGENT. | |
| DE69824313D1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING SIBUTRAMINE AND ORLISTAT | |
| RU2004137823A (en) | THERAPEUTIC AGAINST HYPERCALCEMIC CRISIS | |
| JP2002544227A5 (en) | ||
| KR830002510A (en) | Composition consisting of biologically active compound and hydroxyalkyl starch | |
| ES2111352T3 (en) | USE OF DIESTER PHOSPHATE FOR THE TREATMENT OF RETINAL DISEASES. | |
| RU2004131214A (en) | METHODS FOR TREATING COGNITIVE DISORDERS | |
| AR025549A1 (en) | MICOFELONATE MOFETIL IN ASSOCIATION WITH PEG-IFN-ALFA | |
| Newell | Pharmacokinetically guided dose escalation in phase I clinical trials: Commentary and proposed guidelines. | |
| KR890012942A (en) | 5-substituted ornithine derivatives | |
| RU2006101061A (en) | ASENAPINE FOR THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH OVERBODY WEIGHT OR PREPAREDNESS FOR OVERWEIGHT BODY |